

From sequence data to patient result: a solution for HIV drug resistance genotyping with Exatype, end to end software for Pol-HIV-1 Sequence analysis and patient HIV drug resistance result generation

Leonard King'wara^{1,2*}, Muthoni Karanja², Catherine Ngugi², Geoffrey Kangogo^{1,2}, Kipkerich Bera¹, Maureen Kimani², Nancy Bowen¹, Dorcas Abuya^{1,2}, Violet Oramisi², and Irene Mukui²

Institutional affiliation

1. National Public Health Laboratory (NPHL)
 2. National AIDS and STI Control Program (NASCOP)
- * Corresponding author leonard.kingwara@gmail.com.

1. Leonard King'wara leonard.kingwara@gmail.com
2. Muthoni Karanja evemuthoni2010@gmail.com
3. Catherine Njeri Ngugi ncatherine26@gmail.com.
4. Geoffrey Kangogo geffkemboy@yahoo.com.
5. Kipkerich Bera skipkerich@gmail.com.
6. Maureen Nyambura Kimani maureen.nyambura@gmail.com.
7. Nancy Bowen, njebungeibowen@gmail.com.
8. Dorcas Abuya abuyadorcus@gmail.com.
9. Violet Oramisi oramisi4@gmail.com.
10. Irene Mukui irenemukui5@gmail.com.

1 **Abstract**

2 *Introduction:* With the rapid scale-up of antiretroviral therapy (ART) to treat HIV infection, there
3 are ongoing concerns regarding probable emergence and transmission of HIV drug resistance
4 (HIVDR) mutations. This scale-up has to lead to an increased need for routine HIVDR testing to
5 inform the clinical decision on a regimen switch. Although the majority of wet laboratory
6 processes are standardized, slow, labor-intensive data transfer and subjective manual sequence
7 interpretation steps are still required to finalize and release patient results. We thus set out to
8 validate the applicability of a software package to generate HIVDR patient results from raw
9 sequence data independently.

10 *Methods:* We assessed the performance characteristics of Hyrax Bioscience's Exatype (a
11 sequence data to patient result, fully automated sequence analysis software, which consolidates
12 RECall, MEGA X and the Stanford HIV database) against the standard method (RECall and
13 Stanford database). Exatype is a web-based HIV Drug resistance bioinformatic pipeline available
14 at sanger.exatype.com. To validate the exatype, we used a test set of 135 remnant HIV viral
15 load samples at the National HIV Reference Laboratory (NHRL).

16 *Result:* We analyzed, and successfully generated results of 126 sequences out of 135 specimens
17 by both standard and Exatype software. Result production using Exatype required minimal
18 hands-on time in comparison to the standard (6 computation-hours using the standard method
19 versus 1.5 Exatype computation-hours). Concordance between the two systems was 99.8% for
20 311,227 bases compared. 99.7 % of the 0.2% discordant bases, were attributed to nucleotide
21 mixtures as a result of the sequence editing in Recall. Both methods identified similar (99.1%)

22 critical antiretroviral resistance-associated mutations resulting in a 99.2% concordance of
23 resistance susceptibility interpretations. Base calling comparison between the two methods had
24 Cohen's kappa (0.97 to 0.99) implying an almost perfect agreement with minimal base calling
25 variation. On a predefined dataset, RECall editing displayed the highest probability to score
26 mixtures accurately one vs. 0.71 and the lowest chance to inaccurately assign mixtures to pure
27 nucleotides (0.002–0.0008). This advantage is attributable to the manual sequence editing in
28 RECall.

29 *Conclusion:* The reduction in hands-on time needed is a benefit when using the Exatype HIV DR
30 sequence analysis platform and result generation tool. There is a minimal difference in base
31 calling between Exatype and standard methods. Although the discrepancy has minimal impact
32 on drug resistance interpretation, allowance of sequence editing in Exatype as RECall can
33 significantly improve its performance.

34 **Keywords**

35 Drug Resistance Testing, Validation, Efficiency and Results

36 **Introduction**

37 Human immunodeficiency virus (HIV) drug resistance testing (DRT) has been used by WHO to
38 guide policies relating to antiretroviral treatment (ART) dispensation at an individualized level in
39 clinical practice as well as the public health recommendations for antiretroviral therapy regimens
40 in various populations^{1,2}. Drug resistance testing identifies mutations within the viral genome that
41 confer resistance to the patient regimen, thus allowing healthcare workers to optimize patient
42 treatment, increasing the chance of successful virologic suppression. Furthermore, implementing
43 platforms for drug resistance surveillance at the population level^{3,4} can help minimize the use of
44 ineffective drugs, improving population-wide treatment outcomes, and reducing the risk of
45 transmitted HIV drug resistance⁵⁻⁷. The ThermoFisher in-house genotyping procedure is one of
46 the methods widely used for HIV drug resistance testing.

47 The HIV DRT wet laboratory processes includes several steps such as viral RNA extraction using
48 plasma or dry blood spot (DBS) sample type, reverse transcriptase-polymerase chain reaction
49 PCR (RT-PCR) amplification, nested PCR, gel documentation, nested PCR product clean-up,
50 cycle sequencing, cycle sequencing product clean up and finally population-based (bulk)
51 sequencing^{8,9}. Several sequencing primers depending on the laboratory method, are required
52 during the sequencing step to ensure complete bidirectional coverage over the entire length of
53 the HIV-1 pol region of interest. In our laboratory, a laboratory specialist then assesses the
54 quality of the sequences using an Applied Biosystems (ABI) sequence scanner before transferring
55 ABI sequence trace files from the genetic analyzer to a disc or flash drive. DNA sequence reads
56 from each specimen are then separately assembled into a contiguous consensus sequence in
57 FASTA format by use of RECall analysis software (web or standalone). Sequence scanner and

58 MEGA X is used to assess the quality of the FASTA file for contamination check using
59 phylogenetic analysis method, and eventually transfer to the HIVDB Stanford database for
60 mutation interpretation. These steps require considerable hands-on time as well as a highly
61 trained technician. These steps can be challenging and time-consuming in a busy HIV DRT
62 laboratory that is processing more than 300 samples per week with limited human resources.

63 Despite the number of HIV DR laboratories in resource-limited settings moving to RECall as
64 standard software for contig assembly, resulting in the standardization of result reporting,
65 resistance mutation reporting still varies in some cases between laboratories, even between
66 identical samples^{10,11}. Most of these inter-laboratory discrepancies come from differences in
67 sample preparation procedures (e.g., extraction procedures, primer choice, quality assurance
68 adherence, clean-up processes, or stochastic variation). However, some are still as a result of
69 the change introduced by technicians as they subjectively review the assembled sequences^{12,13}.

70 With the introduction of test and treat policies resulting in rapid ART initiation among those
71 newly diagnosed with HIV¹⁴, most drug-resistant HIV variants are present at low frequencies in
72 clinical isolates. Thus accurate identification of nucleotide "mixtures" (positions having two or
73 more nucleotides) is required, especially for DR surveillance¹⁵⁻¹⁷. Limited laboratory specialist
74 capabilities and experiences in low-level nucleotide mixtures identification could thus result in
75 clinically relevant drug resistance mutations being missed^{10,18}. Even though, standardization of
76 laboratory Quality practices and protocols among the WHO-accredited laboratories has been
77 instituted by external quality assurance program¹⁸, the process does not capture HIV DR testing
78 laboratories out of the WHO HIVResNet even though these laboratories do support the patient

79 diagnosis. Also, despite these QA programs being in place, the impact of erroneous results due
80 to subjective sequence interpretation on patient care is difficult to ascertain.

81 Implementation of automated sequence analysis and result reporting tool would enable objective
82 and consistent interpretation and reporting of HIV genotype data and provide considerable
83 practical advantages to clinicians, patients, and other healthcare workers utilizing the results for
84 patient management. Most notably, it would improve result processing speed and significantly
85 decrease human resource needs that would be apparent in the implementation of routine DR
86 testing in resource-limited settings. The National HIV Reference laboratory in Kenya has thus
87 validated a bioinformatics software tool, Exatype, that has the capabilities to address these
88 challenges. Exatype consolidates the WHO-adopted processes for HIV DR genotyping into a
89 single step - contig assembly, mutation calling, and drug-resistance interpretation are all
90 automated. Specifically, Exatype includes the RECall software to interpret and analyze
91 chromatograms and the Stanford HIVDB drug resistance algorithm for drug-resistance
92 interpretation. Besides, it contains genetic distance analysis that allows for the detection of
93 contamination. As an automated process, Exatype is to support HIV DR testing laboratories with
94 a heavy workload. It combines the functionalities of RECall, Stanford HIV drug resistance
95 database (HIVDB) and, MEGA X programs and is available at sanger.exatype.com.

96 In this paper, we present field validation results for automated Exatype analysis and reporting of
97 HIV DR results.

98

99 **Materials and methods**

100 **Laboratory methods** HIV drug resistance testing was performed at the National HIV
101 Reference laboratory in Kenya. Using 1000 copies/ml program guidelines cut off for viral
102 suppression as the test kit sensitivity limit, we picked remnant samples from the HIV RNA
103 measurement section after HIV-I viral load testing²⁰. We performed HIV genotypic resistance
104 testing on 135 remnant patient samples. We did plasma virus extraction using the ThermoFisher
105 Kingfisher flex platform followed by one-step RT-PCR, denaturing of amplicons, and finally, a
106 nested second-round PCR. For QA purposes, we assessed the PCR product on a gel. The
107 cleanup procedure used Exosap before proceeding to cycle sequencing. Also, sequence product
108 purification used x-terminator. An ABI 3730xl performed direct bi-directional sequencing
109 encompassing HIV-I protease (PR) and the first 296 codons of reverse transcriptase (RT).
110 Sequencing Analysis v 5.2 (ABI) assisted in reading the chromatograms. For quality assurance,
111 nucleotide mixtures (positions containing two or more nucleotides, with the minor peak height
112 being $\geq 20\%$ of the significant peak height, were marked with ABI 3730xl data collection
113 software v 3.30.

114 **Standard analysis procedure** After the necessary sequence QA procedures using a sequence
115 scanner, a laboratory specialist assembles the sequence trace files for each sample to generate a
116 consensus sequence using standalone RECall software. This software assists the specialist by
117 highlighting areas of conflicts as nucleotide positions with mixture and where overlapping
118 sequence positions do not have the same base call (20% threshold). N is used to mark
119 undistinguished regions of the sequence chain. The laboratory specialist then visually inspects
120 each sequence, stopping at each conflict and making manual edits where necessary. This
121 verification is to ensure that any variations are verified. The generated consensus sequence for

122 each sample is then subjected to MEGA X for contamination check analysis and later to Stanford
123 HIVDB to create patients' results. In addition to the 135 patient specimens, we included 40 EQA
124 dry panels from the WHO ResNet Lab group to ensure that the study conforms to the Clinical
125 and Laboratory Standard Institute CLSI guidelines on laboratory method validations.

126 **Besides the standard method, we used Exatype** to reanalyze and generate results from
127 3730xl ABI trace files without sequence editing. Similarly, to RECall, overlapping peaks
128 represents “mixed or ambiguous” bases. The location of the primary peak (called base) and the
129 most significant secondary peak (uncalled base) in the trace file are determined by phred. It then
130 aligns the peak positions to their corresponding locations in the .abi data as most primary and
131 secondary peaks often offset. Poor sequence quality regions at the beginning and end of each
132 fragment are then automatically identified and trimmed. All chromatograms (.abi) were
133 submitted to Exatype and processed without any human intervention, using a standard laptop
134 (Asus-i3 660 3.33-GHz CPU, 3 GB RAM, Windows 2010).

135 **Exatype nucleotide mixture calling and “marking” of potentially problematic bases** The
136 essential feature of Exatype is its consolidated workflow, where no file transfer between
137 separate software programs is necessary. The contig assembly and FASTA file generation (by
138 implementing RECall) and the subsequent interpretation by Stanford HIVDB is done
139 automatically, without any editing or file transfer to MEGA X for contamination check or
140 Stanford HIVDB for result generation. Following the assembly and alignment step, mixtures
141 categorization is based on the quality and area under the curve of the called and uncalled base as
142 determined by Phred using a built-in RECall software. Configuration for RECall, within Exatype,
143 variables that guide its mixture calling for clinical drug resistance testing at the National HIV

144 Reference Laboratory (NHRL) are listed in **Table 2**. The examination of each position in the
145 sequence alignment sequentially and the samples that require manual editing are marked.

146 **Exatype pass-fail criteria at the laboratory level** We performed quality checks on every
147 sample trace file to ensure that the sequence was acceptable. Table 2 lists the sequence
148 rejection criteria. Once the trace file is uploaded to Exatype, and it passes the RECall specified
149 internal quality control checks, it automatically generates sample results and corresponding
150 FASTA files. At present, the software requires double primer coverage over the entire sequence
151 length. We included only analyses that passed the Exatype-implemented quality control criteria
152 in this study.

153 **Subtyping and phylogenetic analysis**

154 One hundred and twenty-six samples were successfully extracted, amplified for the *gag* gene in a
155 nested PCR, and sequenced. Generated sequences (approximately covering 460–470 bp of p24
156 and p7 region of *gag* gene, NT 1577–2040, HXB2) were then used for sequence alignment using
157 RECall and to construct the phylogenetic trees using the neighbor-joining method with PAUP.
158 Alignment of generated sequences with Los Alamos database reference sequences revealed that
159 54 (43%), 31 (25%), 14 (11%), and 8 (6%) of the 126 specimens are subtype A, D, C, and G
160 respectively. *Simplot* analysis revealed a few recombinant types in our study samples: 7 (6%)
161 being AD, 2 (2%) AC, 2 (2%) AG and 8 (6%) CRF01_AE ([Table 1](#)).

162 **Data analyses:** We compared the consensus sequences and results generated by the standard
163 method and Exatype. Speed, concordance of base calls, and results were used to assess the
164 performance of Exatype. Partial nucleotide discordance is when one methodology reported a

165 nucleotide mixture, and the other reported one of the mixture's components (e.g., RECall
166 reported Y and Exatype reported C). Complete nucleotide discordance is when the two-analysis
167 method used, indicate different nucleotide at the same position for the same sample (e.g., RECall
168 reported T and Exatype indicate C). Similarly, this can occur in a mixture when nucleotide called
169 by one method is different from the other (e.g., RECall reported G and Exatype indicate Y).

170
171 We also compared the analysis of specific antiretroviral drug resistance mutation positions as
172 defined by International AIDS Society (USA table) on key resistance mutations. We processed
173 126 samples on Stanford HIV drug resistance genotyping Web service Sierra (algorithm version
174 8.8 [http://hivdb.stanford.edu/pages/algs/sierra_sequence.html]; Stanford University, Stanford,
175 CA) to infer antiretroviral drug susceptibilities in RECall analyzed PR-RT nucleotide sequences.
176 ANRS version 27, HIVDB version 8.9-1, and REGA version 8.0.2 reanalyzed the samples. For,
177 10% false-positive rate (FPR) or 20% FPR cut-off, we used G2P Geno2Pheno for prediction in
178 the coreceptor.

Number of remnant clinical samples used

Subtype A	54(43%)
Subtype D	31(25%)
Subtype C	14(11%)
Subtype G	8(6%)
Subtype AD	7(6%)
Subtype AC	2(2%)
Subtype AG	2(2%)
Subtype CRF01_AE	8(6%)
VL < 1000 cp/ml	34(27%)
VL > 1000 cp/ml	92(73%)

Therapy naive	9(7%)
Therapy experience	103(82%)
Therapy unknown	14(11%)

179 Table 1: Distribution of the HIV-1 subtype in the samples used for validation

Parameter	Value	Interpretation
Quality censoring cutoff	< 10	<i>Phred quality scores cut off for excluding bases during assembly.</i>
Mixture area (%)	≥ 20	<i>The area of the uncalled peak must be at least 20% of the called peak area. If $\geq 50\%$ of the reads pass this threshold, then a mixture is called.</i>
Mark area (%)	≥ 15	<i>The area of the uncalled peak must have at least 17.5% of the called peak area. If $\geq 50\%$ of the reads pass this threshold, then a mark is made.</i>
Mark average quality cut-off phred score Additional marks	< 20	<i>If the average quality of the base across all reads is below the cutoff, then a mark is made. Insertions, deletions, and single primer coverage are also marked.</i>

180 Table 2: Configuration variables for nucleotide mixture calling and base “marking” for clinical drug resistance

181 genotyping^{22,23}

182

Failure category	Description
Stop codon	<i>Any unambiguous stop codon (TGA, TAA, or TAG)</i>
Bad inserts	<i>An insertion relative to the reference sequence that is not a multiple of three</i>

	<i>bases, resulting in a frameshift</i>
Bad deletion	<i>A deletion relative to the reference sequence that is not a multiple of three bases, resulting in a frameshift</i>
Too many mixtures	<i>>3.5% of nucleotides sequences called as mixtures</i>
N count	<i>>=5 Ns (any base) in the sequence</i>
Mark count	<i>>= 100 positions marked as being potentially problematic</i>
Single coverage	<i>>3 consecutive bases of single-read coverage with phred scores of 40</i>
Low quality	<i>Any section where the quality of all coverage is too low to make a call</i>

183 **Table 3: Criteria used by RECall for rejecting a sequence** ^{9,18}

184 **Ethics statement** Amref Health Africa Research Ethics Committee approved the study (Ref
185 No, 4562). We used the principles of the international Declaration of Helsinki 2013 and Good
186 clinical laboratory practices to conduct the research. The study used a waiver of consent to
187 conduct analyses on the remnant HIV viral load samples. Patients were receiving clinically
188 significant results.

189 **Results**

190 RECall was able to generate a consensus sequence for 9.8% (132/135) of the pol experiments,
191 whereas Exatype was successful in 93.3% (126/135) of the tests (**Table 4**). Of these, 126
192 (93.3%) met the default Exatype and RECall acceptability criteria after automated processing.
193 Inadequate double primer coverage over the entire sequence length was the primary reason for

194 failure. For the standard analysis using a standard Laptop (ASUS-i3 660 3.33-GHz CPU, 3 GB
195 RAM, Windows XP), we performed RECall base calling, assembly, contamination check using
196 MEGA X and alignment in less than 4 hours, with human sequence edit review. We then
197 proceeded and used Stanford HIVDB to generate patient results in one hour.

198 In contrast, we did the entire analysis, QA contamination report generation, and patient result
199 generation in Exatype on the same laptop within one hour. The longer time in the standard
200 software pipeline is attributed from the sequence review and edits before exporting the contig
201 into a different software MEGA X for QA analysis and Stanford HIVDB for patient result
202 generation. All the steps are performed simultaneously in Exatype.

Editing method	Results	No Results	Total
Exatype	126 (93%)	9 (7%)	135
Standard analysis Procedure	132 (98%)	3 (2%)	135

203 **Table 4: Performance in generating consensus pol sequences for HIV-1 samples by the different editing approaches.**

204 **Nucleic acid sequence concordance between Exatype and Standard analysis procedure**

205 Within 311,227 analyzed bases, there was 99.8% overall agreement in base calling between
206 Exatype and the gold standard. There was 99.6% complete sequence concordance within
207 311,227 nucleotide positions, as indicated in **Fig. 1**. Of the 311 discordant nucleotides, 308
208 (99%) were “partially discordant” (mixtures called by one method but not the other), while 3
209 (1%) were wholly discordant. 76.5% (238 of 311) of the partially different bases comprised of
210 nucleotide pairs as a result from transitions (R A/G, Y C/T) rather than transversions (K G/T, M
211 A/C, S C/G, W A/T).


212 Distribution of discordant positions between the transitions, transversions, and a combination of
 213 both was relatively the same (n 11, 6, and 5, respectively), as indicated in **Fig. 1**. 1.2% of
 214 nucleotide mixtures detected on all bases. Overall, the standard method called a marginally
 215 more significant number of mixtures (1193 standard method -called mixtures [1.08%] and 1181
 216 Exatype-called mixtures [1.05%]; P 0.6).

217 **Amino acid sequence concordance between Gold standard and Exatype**
 218 **interpretations** the 311 discordant nucleotide positions resulted in 284 discordant codons. 114
 219 (40.1%) of these, produced Nonsynonymous substitutions between the standard and Exatype
 220 method at the sequence to amino acid translation level. 278 (97.8%) were partial amino acid
 221 discordances (sharing at least one amino acid between the two interpretations), while only 6
 222 (2.2%) were complete amino acid differences.

223 In general, the gold standard and Exatype sequence review identified 97 “key” antiretroviral
 224 drug resistance mutations²⁴, as either complete amino acid substitutions or as part of mixtures.
 225 The two methods agreed for 123 cases. The Exatype identified one resistance mutation (E35D)
 226 that the gold standard did not, while the gold standard identified 2(K55R and R57K) that Exatype
 227 did not. This variation in resistant mutation identification affected two patient results though
 228 none of the three mutations has clinical significance

229

The gold standard(RE-call)											
		A	C	G	T	R	Y	W	S	M	K
call	A	151,254				42		25	1	9	
	C		78,562				14		1	4	1



230 **Figure 1** Concordant and discordant nucleotide base call in sequences analyzed by Gold standard and by Exatype. Matrices depict the
 231 frequencies of nucleotides called by Exatype (vertical axis) and by Standard (horizontal axis). Green highlight implies a concordant base call.
 232 Partially discordant base calls (implies mixtures called by one method but not the other) is in yellow highlight. Entirely discordant base calls are in
 233 red highlight. Zero is represented by blank cells. International Union of Biochemistry and Molecular Biology ambiguity codes are as follows; R
 234 A/G, Y C/T, W A/T, M A/C, K G/T, S G/C, B C/G/T, D A/G/T, H A/C/T, and V A/C/G. Overall, 99.8% concordance was observed for 311,227
 235 bases compared.

	#	# WITH	# WITH							
		WITH	DIFFERENCES	RESISTANCE	INTERPRETA	TION				
REGI	#	# with	Difference	Differ	Gap	Error	Error			
ON		NT	Mix	ent	manual ^c	Manual ^d	Exatype ^e			
		differen		NT ^b						
		ces								
PR	126	17	0	0	3	9	24	24	1	(ANRS)
RT	126	32	4	1	1	8	31	54	1	(ANRS);

236 **Table 5:** Differences in Gold standard and Exatype editing of HIV-1 pol sequences from clinical samples and impact
237 on drug resistance interpretation. We considered sequences that passed both Exatype and Gold standard editing. #, number of
238 samples; NT, nucleotide; AA, amino acid; genotypic drug resistance interpretation systems: ANRS version 27, HIVDB version 8.9-1, and
239 REGA version 8.0.2. We used G2P Geno2Pheno for prediction in coreceptor use when cut-off of 10% false-positive rate (FPR) or 20%
240 FPR.

- 241 a) Number of samples with mixtures scored differently by the two approaches
- 242 b) Number of samples with pure nucleotides scored separately by the two approaches
- 243 c) Number of samples with parts of sequences that were not analyzable as judged by the editor
- 244 d) The number of samples containing differences between Recall and Exatype editing due to manual editing.
- 245 e) Number of samples containing differences between Exatype and Recall editing due to errors made during
246 automatic editing in Exatype

247 From the HIV-1 RNA measurement remnant samples, 93.3% (126/135) of the pol HIV-1 had a
248 consensus NT sequences available and generated by both Exatype and RECall (Table 5). In total,
249 86.5% (109/126) of the PR, 74.6% (94/126) of the RT sequences were fully concordant at the
250 NT level. At the AA level, 81% (102/126) of the PR, 51.1% (72/126) of the RT samples were
251 the same. The differences in concordance between the different regions were attributed to the
252 difference in coverage length and were less pronounced when normalized.

253 For each discordant NT call, the chromatograms were manually reviewed by a second
254 laboratory specialist to verify whether the differences resulted from an erroneous call in the
255 automatic or manual editing process. For both editing approaches, incorrect calls were
256 observed, i.e., in 24 vs. nine samples for PR, 31 vs. 1 for RT (Table 5). Only 1 RT nucleotide was
257 different between the manually and automatically edited sequences. In both instances,
258 differences result from mistakes made during manual editing. The operator trimmed the five

259 ends of PR in 3 samples and one sample for RT, but these parts were still completely analyzed by
 260 RECall and not Exatype. Additionally, some of the erroneous calls in Exatype were because this
 261 tool does not allow sequence editing.

	# WITH NT DIFFERENCES COMPARED TO THE REFERENCE SEQUENCE								# WITH AA DIFFERENCES		# WITH DIFFERENCES IN RESISTANCE INTERPRETATION						
	PR				RT				PR	RT	PR			RT			
	To tal	Misse d mix	False mix	Different NT/mix	To tal	Misse d mix	False mix	Different NT/mix			A	HIV	RE	A	HIV	RE	
EXA	22/	5/	2/2	3/3	1/-	2/-	1/-	1/-	-/-	3/4	2/-	-/-	-/-	-/-	-/-	-/-	-/-
TYPE	10	4															
REC	22/	5/	1/1	3/2	1/-	-/2	-/-	-/2	-/-	2/3	-/-	-/-	-/-	-/-	-/-	-/-	-/-
ALL	12	3															

262 **Table 6: Differences in RECall and Exatype editing of HIV-1 pol sequences from all EQA samples and impact on drug**
 263 **resistance interpretation.** This analyses were confined to drug resistance positions (PR: 10, 20, 24, 30, 32, 33, 36, 46, 47, 48, 50, 53, 54, 63,
 264 71, 73, 77, 82, 84, 88, 90; RT: 41, 62, 65, 67, 69ins, 69, 70, 74, 75, 77, 100, 103, 106, 108, 115, 116, 151, 181, 184, 188, 190, 210, 215, 219,
 265 225). #, number of samples; PR, protease; RT, reverse transcriptase; NT, nucleotide; AA, amino acid; genotypic drug resistance interpretation systems:
 266 ANRS version 27, HIVDB version 8.9-1 and REGA version 8.0.2. The number of sequences that passed Exatype and RECall editing are before the slash.
 267 Number of sequences that did not pass either of the two approaches are behind the slash

- 268 I. The number of samples with mixtures present in the reference sequence, but not scored by the editing approach (pure wild-type or mutant
 269 NT).
- 270 II. The number of samples with mixtures scored by the editing approach that was not present according to the reference sequence (pure wild-
 271 type or mutant NT).
- 272 III. Number of samples with mixtures and pure nucleotides scored differently by the editing approach and the reference sequence

273 **85% (22 + 12 = 34)/40) of the EQA dry panels (These are FASTA files shared by the WHO to**
 274 **all the WHO accredited lab for competency assessment of staff in sequence editing) from WHO**
 275 **had a consensus sequence using Recall, while for the Exatype, it was 80% (32/40) (Table 6). For**

276 each dry panel, a reference sequence sent by WHO was considered as the accurate results, and
 277 was calculated based on the consensus results of all participants within the WHO ResNet Lab
 278 (~52 participants). We further reviewed each discordant NT call to find out whether the
 279 difference resulted from a missed mixture, a false mixture, or a different NT or mixture (Table
 280 6). Both Recall and Exatype are comparable in terms of detecting mixtures with both almost
 281 having a similar score on the mixtures that were not present in the reference sequence (Table
 282 6).

	RECALL		EXATYPE	
	PR	RT	PR	RT
# SEQUENCES WITHOUT NT DIFFERENCES	28/34(82%)	32/34(94%)	24/32(75%)	30/32(94%)
# SEQUENCES WITHOUT AA DIFFERENCES	30/34(88%)	34/34(100%)	26/32(81%)	30/32(94%)
# NT DIFFERENCES/TOTAL # NT	9/2112(0.43%)	1/2562(0.04%)	18/2023(0.88%)	4/2400(0.17%)
# AA DIFFERENCES/TOTAL # AA	5/724(0.72%)	0/912(0%)	10/675(1.48%)	2/800(0.25)
# $M_E \cap M_R$	18	18	12	8
# M_R	21	19	16	11
$P(M_E M_R)$	0.83	1	0.7	0.85
# $M_E \cap P_R$	7	2	8	1
# PR	2081	2679	1999	2381
$P(M_E P_R)$	0.002	0.0008	0.004	0.0004

283 Table 7: Comparison of RECall, Exatype editing of WHO dry sample EQA panel with the reference sequence at NT and AA
 284 level. To meet the CLSI guidelines of 40% reference panels being EQA standards, we included dry panels from the WHO ResNet group. #, number of;
 285 AA, amino acids; NT, nucleotides; M_e , mixtures present in the results of the editing approach; M_r , mixtures present in the reference sequences; $M_e \cap M_r$,
 286 mixtures present in the reference sequences that scored as a mixture by the editing approach; P_r , pure nucleotides present in the reference sequences;
 287 $P(M_e | M_r)$, the probability that a mixture scored if present in the reference sequence; $M_e \cap P_r$, pure nucleotides in the reference sequences that scored as
 288 a mixture by the editing approach; $P(M_e | P_r)$, the probability that a mixture scored if no mixture was present in the reference sequence

289 At the NT level, the percentage of sequences without differences compared to the reference
 290 sequence is the slightly lower for Exatype editing, which is 75% and 94% for PR and RT,

291 respectively vs. 82% and 94% for RECall editing (Table 7). Using Recall, 0.43% of the PR and
 292 0.04 % of the RT nucleotides were discordant with the reference sequence, in contrast to
 293 0.88% of the PR and 0.17% of the RT nucleotides using Exatype which was markedly higher.
 294 The same tendency observed at the AA level (Table 7). We then assessed for editing approach,
 295 the probability $P(M_e|M_r)$ that a mixture scored if the mixture was present in the reference
 296 sequence and the probability $P(M_e|P_r)$ that a mixture scored yet it was a pure nucleotide
 297 sequence.

298 In the remnant HIV-1 RNA samples, the majority of samples for which at least one of the editing
 299 approaches was able to generate a consensus NT sequence were interpreted as susceptible to
 300 most PI, NRTI, and NNRTI and scored as using the CCR5 coreceptor (Table 8) solely. Also,
 301 much more extensive drug resistance profiles observed in the WHO dry panel as compared to
 302 the clinical dataset (Table 8).

303

DATA SET	ACCORDIN G TO	ANRS		HIVDB		REGA		G2P	G2P FPR
		PI	RTI	PI	RTI	PI	RTI	FPR 10%	20%
								CCR5	CCR5
								antagonists	antagonists
CLINICAL	Exatype	82/126	51/126	33/126	42/126	34/126	41/126	49/126	50/126
	FASTA file	(65%)	(41%)	(26%)	(33%)	(27%)	(33%)	(39%)	(40%)
	RECall	81/126	52/126	33/126	42/126	34/126	43/126	48/126	50/126
	FASTA file	(64%)	(41%)	(26%)	(33%)	(27%)	(34%)	(38%)	(40%)
WHO DRY PANEL	Reference	18/40	20/40	18/40	20/40	17/40	20/40		
		(45%)	(50%)	(45%)	(50%)	(43%)	(50%)		

304 **Table 8:** Number of samples displaying (intermediate) resistance to different drug classes, according to ANRS, HIVDB, REGA, and Geno2Pheno.

305 *For the HIV-1 RNA remnant dataset, we included only the sequences that passed for both RECall, and Exatype editing. In contrast, we included*

306 *resistance information of all reference sequences for the WHO dry panel dataset. FPR, false-positive rate; RTI, reverse transcriptase inhibitor; PI,*

307 *protease inhibitor; genotypic drug resistance interpretation systems: ANRS version 27, HIVDB version 8.9-1 for the clinical dataset and HIVDB version*
308 *8.9-1 for the EQA dataset, and REGA version 8.0.2, G2P Geno2Pheno*

309

310 **Discussion**

311 The study evaluated the performance characteristics of the Exatype sequence analysis and result
312 generation tool developed by Hyrax Biosciences, the ability to accurately analyze and interpret
313 ABI sequence data into patient results. Exatype is freely available for ThermoFisher HIV-1
314 Genotyping Kit users at sanger.exatype.com. We compared the results (FASTA files and patient
315 results) generated by Exatype against our laboratory gold standard method (RECall and Stanford
316 HIVDB. Using a set of 135 sequences, we assessed the proportion successfully analyzed by both
317 methods, as well as the concordance of detection of ambiguous nucleotides, amino acid changes,
318 and drug resistance mutations between the sequences and results generated by the gold
319 standard (Recall and Stanford) and Exatype. While the gold standard produced results for 132
320 samples, Exatype only produced results for 126. For the 126 (93%) for which results were
321 available from both methods, there was a concordance of 99.8% between the two methods
322 similar to other sequence analysis software comparisons^{12,24}. The minor differences were
323 attributed to the partial nucleotide discordance, one method detected a mixture and the other
324 detected one component of the mixture. This consequently resulted in partial discordance for
325 amino acids too.

326 Exatype and the gold standard had a concordance of 99.1% on NRTI/NNRTI resistance
327 mutations. This is similar to the inter-personnel skill variability on sequence editing^{25,26},
328 depending on the sample tested. The one key resistance mutation mixture that was not

329 detected by the Gold standard and the two that were not detected by Exatype were as a result
330 of partial mismatches due to differential detection of nucleotide mixtures. Despite the high
331 concordance, the inflexibility of a fully automated system may be a drawback to the Exatype
332 system, as the result of this study show in the two key mutations missed. Exatype as the gold
333 standard mark unusual sequence positions, including mixtures, which someone can visually
334 inspect. In our case, Exatype didn't have any human intervention.

335 The difference in the numbers of mixtures called between Exatype and the standard method
336 was not statistically significant, making Exatype a vital data analysis standardization tool,
337 especially in clinical reporting, which cannot be achieved by the gold standard method²⁷⁻²⁹. Edits
338 in Exatype are similarly traceable in a separate note pad within the batch system for all the
339 results that are analyzed. This availability makes it compliant to Good Clinical Laboratory
340 Practice (GCLP) standards call for traceability of data in the case of manual edits. Also, Exatype
341 significantly improves the efficiency of HIV drug resistance genotyping and patient reporting. It
342 removes the manual procedure of data transfer and sequence editing that is currently in the gold
343 standard.

344 The study indicates that the Exatype editing tool had the comparably underestimates the
345 presence of mixtures as opposed to RECall. The discordances in Exatype within the pol
346 sequences were limited to 0.17–1.48% at the NT and AA level, with limited impact on drug
347 resistance interpretations. RECall editing performed slightly better than Exatype editing, as it
348 displayed the highest probability to score mixtures accurately (0.83–1) vs (0.7–0.81). The lowest
349 probability to inaccurately assign mixtures to pure nucleotides (0.002–0.0008). This low
350 probability is attributable to the allowance of sequence editing with RECall. This study also

351 highlighted the necessity of a second inspection as erroneous calls were not only made during
352 automatic but also manual editing. In this respect, Exatype can be made better by allowing
353 sequence editing before result generation.

354

355 **Conclusion**

356 RECall editing performed slightly better than Exatype editing, as it displayed the highest
357 probability to score mixtures accurately (0.83–1) vs (0.7– 0.81) and the lowest probability to
358 inaccurately assign mixtures to pure nucleotides (0.002–0.0008). This is attributed to the
359 allowance of sequence editing with Recall. Our results show that Exatype can provide an
360 objective, standardized protocol for HIV sequence analysis for routine patient drug resistance
361 testing and research laboratories, though allowance should be given to allow for sequence
362 editing before result generation for it to be comparable to Recall. The speed and removal of data
363 transfer when using the Exatype is the primary advantage as it removes the sequence edit and
364 the MEGA X QA analysis steps. The system standardizes the laboratory data analysis procedures
365 and thus facilitates unbiased sequence interpretation. We did not factor in the software cost
366 especially for laboratories that are not using the ThermoFischer in-house assay

367

368 **Declarations**

369

370 **Ethics approval and consent to participate**

371 The study was approved by the Amref Health Africa institutional ethics review committee. This
372 was a retrospective study using remnant viral load samples and the consent of patients to

373 participate was not required.

374 **Consent for publication**

375 Not applicable

376 **Availability of data and material**

377 All data contained within the article are publicly available?

378 **Competing interests**

379 None declared.

380 **Funding**

381 None

382 **Authors' contributions**

383 LK conceived the study, collected data, analyzed the data and drafted the manuscript; IM
384 supervised data collection, contributed to data analysis and assisted in drafting and submission of
385 the manuscript. CN, GK, KB, MNK, NB, VO, and DA participated in data collection and review
386 of the manuscript, MK contributed to data analysis, drafting and critical revision of the
387 manuscript. All authors approved the final version of the manuscript.

388 **Acknowledgments**

389 We acknowledge the Ministry of Health Kenya through the National Public Health Laboratory
390 (NPHL) and the National AIDS and STI Control Program (NASCOP) for facilitating sample
391 collection and allocating staff time to write this manuscript. We thank Peter Young, U.S. Centers
392 for Disease Control and Prevention, Kenya, for reviewing a draft of this manuscript.

393

394 **References**

395

396 1. Baxter, J. D. *et al.* A randomized study of antiretroviral management based on plasma

397 genotypic antiretroviral resistance testing in patients failing therapy. *AIDS* (2000)

398 doi:10.1097/00002030-200006160-00001.

399 2. Meynard, J. L. *et al.* Phenotypic or genotypic resistance testing for choosing antiretroviral

400 therapy after treatment failure: A randomized trial. *AIDS* (2002) doi:10.1097/00002030-

401 200203290-00008.

402 3. DeGruttola, V. *et al.* The relation between baseline HIV drug resistance and response to

403 antiretroviral therapy: Re-analysis of retrospective and prospective studies using a

404 standardized data analysis plan. in *Antiviral Therapy* (2000). doi: 10846592.

405 4. Vaerenbergh, K. Van. Study of the impact of HIV genotypic drug resistance testing on

406 therapy efficacy. *Verh K Acad Geneesk Belg* (2001).

407 5. Rhee, S. Y. *et al.* HIV-1 drug resistance mutations: Potential applications for point-of-care

408 Genotypic resistance testing. *PLoS One* (2015) doi: 10.1371/journal.pone.0145772.

409 6. Weinstein, M. C. *et al.* Use of genotypic resistance testing to guide HIV therapy: Clinical

410 impact and cost-effectiveness. *Ann. Intern. Med.* (2001) doi:10.7326/0003-4819-134-6-

411 200103200-00008.

412 7. Sendi, P. *et al.* Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-

413 infected patients with treatment failure. *PLoS One* (2007)

414 doi: 10.1371/journal.pone.0000173.

415 8. Chroma, M. & Kolar, M. Genetic methods for detection of antibiotic resistance: Focus on

416 extended-spectrum β -lactamases. *Biomed. Pap.* (2010) doi: 10.5507/bp.2010.044.

417 9. Cockerill, F. R. Genetic methods for assessing antimicrobial resistance. *Antimicrobial*

- 418 *Agents and Chemotherapy* (1999) doi:10.1128/aac.43.2.199.
- 419 10. Ewing, B. & Green, P. Base-calling of automated sequencer traces using phred. II. Error
420 probabilities. *Genome Res.* (1998) doi:10.1101/gr.8.3.186.
- 421 11. Tuma, J. M., & Pratt, J. M. (1982). Clinical child psychology practice and training: A survey.
422 *Journal of Clinical Child & Adolescent Psychology*, 137(August 2012), 37–41.
423 <http://doi.org/10.1037/a0022390> et al. How SAGE has shaped Research Methods. A 40-
424 Year History. *Thousand Oaks* (2009).
- 425 12. Prosdocimi, F., Peixoto, F. C. & Ortega, J. M. {DNA} sequences bases calling by
426 {PHRED}: error pattern analysis. *Rev. Tecnol. da Information* (2003).
- 427 13. Hillier, L., Ewing, B., Green, P. & Wendl, M. C. Base-calling of automated sequencer
428 traces using phred. I. Accuracy assessment. *Genome Res.* (1998) doi:10.1101/gr.8.3.175.
- 429 14. Brown, L. B. et al. High levels of retention in care with streamlined care and universal test
430 and treat in East Africa. *AIDS* (2016) doi:10.1097/QAD.0000000000001250.
- 431 15. Power, R. A. et al. Genome-wide association study of HIV whole genome sequences
432 validated using drug resistance. *PLoS One* (2016) doi:10.1371/journal.pone.0163746.
- 433 16. Brumme, C. J. & Poon, A. F. Y. Promises and pitfalls of Illumina sequencing for HIV
434 resistance genotyping. *Virus Research* (2017) doi:10.1016/j.virusres.2016.12.008.
- 435 17. Lapointe, H. R. et al. HIV drug resistance testing by high-multiplex 'Wide' sequencing on
436 the MiSeq instrument. *Antimicrob. Agents Chemother.* (2015) doi:10.1128/AAC.01490-15.
- 437 18. Ewing, B., Hillier, L. D., Wendl, M. C. & Green, P. Base-calling of automated sequencer
438 traces using phred. I. Accuracy assessment. *Genome Res.* (1998) doi:10.1101/gr.8.3.175.
- 439 19. Galli, R. A., Sattha, B., Wynhoven, B., O'Shaughnessy, M. V. & Harrigan, P. R. Sources and
440 magnitude of intralaboratory variability in a sequence-based genotypic assay for human

- 441 immunodeficiency virus type I drug resistance. *J. Clin. Microbiol.* (2003)
442 doi:10.1128/JCM.41.7.2900-2907.2003.
- 443 20. Praparattanapan, J. et al. Comparison of in-house HIV-I genotypic drug resistant test with
444 commercial HIV-I genotypic test kit. *Asian Biomed.* (2011) doi:10.5372/1905-
445 7415.0502.032.
- 446 21. Smith, T. F. & Waterman, M. S. Identification of common molecular subsequences. *J. Mol.*
447 *Biol.* (1981) doi:10.1016/0022-2836(81)90087-5.
- 448 22. Mardis, E. R. New strategies and emerging technologies for massively parallel sequencing:
449 Applications in medical research. *Genome Medicine* (2009) doi:10.1186/gm40.
- 450 23. Bertelli, C. & Greub, G. Rapid bacterial genome sequencing: Methods and applications in
451 clinical microbiology. *Clinical Microbiology and Infection* (2013) doi:10.1111/1469-
452 0691.12217.
- 453 24. Liu, T. F. & Shafer, R. W. Web Resources for HIV Type I Genotypic-Resistance Test
454 Interpretation. *Clin. Infect. Dis.* (2006) doi:10.1086/503914.
- 455 25. Shafer, R. W. et al. High degree of interlaboratory reproducibility of human
456 immunodeficiency virus type I protease and reverse transcriptase sequencing of plasma
457 samples from heavily treated patients. *J. Clin. Microbiol.* (2001)
458 doi:10.1128/JCM.39.4.1522-1529.2001.
- 459 26. Steegen, K. et al. Feasibility of detecting human immunodeficiency virus type I drug
460 resistance in DNA extracted from whole blood or dried blood spots. *J. Clin. Microbiol.*
461 (2007) doi:10.1128/JCM.00814-07.
- 462 27. Merigan, T. C. et al. High Degree of Interlaboratory Reproducibility of Human
463 Immunodeficiency Virus Type I Protease and Reverse Transcriptase Sequencing of

- 464 Plasma Samples from Heavily Treated Patients. *J. Clin. Microbiol.* (2002)
465 doi: 10.1128/jcm.39.4.1522-1529.2001.
- 466 28. R.W., S., A., W., M.A., W. & M.J., G. Reproducibility of human immunodeficiency virus
467 type I (HIV-1) protease and reverse transcriptase sequencing of plasma samples from
468 heavily treated HIV-1-infected individuals. *J. Virol. Methods* (2000) doi: 10.1016/S0166-
469 0934(00)00144-0.
- 470 29. Shafer, R. W., Warford, A., Winters, M. A. & Gonzales, M. J. Reproducibility of human
471 immunodeficiency virus type I (HIV-1) protease and reverse transcriptase sequencing of
472 plasma samples from heavily treated HIV-1-infected individuals. *J. Virol. Methods* (2000)
473 doi: 10.1016/S0166-0934(00)00144-0.
474